New Indication: Axitinib for unresectable recurrent or metastatic head and neck cancer

New Indication: Axitinib for unresectable recurrent or metastatic head and neck cancer

Single-arm phase 2 trial
Unresectable recurrent or metastatic (R/M) head and neck squamous cell carcinoma (n=29)
61% had at least 1 previous systemic treatment
Results: Median OS: 9.8 mos. 6-month OS: 70%
ORR: 42% => ORR higher in those with PI3K pathway alterations (75% vs. 17%)

Swiecicki PL, et al. Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria. Cancer.
https://doi.org/10.1002/cncr.33226

Reviewed by Ulas Darda Bayraktar, MD on Nov 2, 2020

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More